PainCeptor Pharma
From Wikipedia, the free encyclopedia
 |
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (February 2009) |
PainCeptor Pharma is a private Canadian company focused on the development of drugs that act outside the central nervous system on nociceptors to treat pain.[1] The company's strategic focus on peripheral rather than central acting therapeutics is an attempt to avoid the known side-effects of existing central acting agents.[2] The primary molecular targets addressed by PainCeptor are members of the ASIC ion channel family and nerve growth factor (NGF) and NGF receptors.[2] Though PainCeptor refers to itself as a biopharmaceutical company on its website,[1] its two primary publicly reported drug discovery projects aim to deliver small molecule therapeutics.[2]
[edit] References
- ^ a b "PainCeptor Pharma corporate home page". PainCeptor Pharma public corporate website. http://www.painceptor.com. Retrieved 2007-10-18.
- ^ a b c Dimond, Patricia F. (2007-10-01). "Revamping Drug Discovery Strategies". Drug Discovery (Genetic Engineering News). http://www.genengnews.com/articles/chitem.aspx?aid=2245. Retrieved 2007-10-18.
[edit] External links
 |
This article about a Canadian corporation or company is a stub. You can help Wikipedia by expanding it. |
